View ValuationEden Research 将来の成長Future 基準チェック /26Eden Researchの収益は年間8.4%で減少すると予測されていますが、年間収益は年間34.6%で増加すると予想されています。EPS は年間13.2%で増加すると予想されています。主要情報-8.4%収益成長率13.25%EPS成長率Chemicals 収益成長43.1%収益成長率34.6%将来の株主資本利益率n/aアナリストカバレッジLow最終更新日28 Apr 2026今後の成長に関する最新情報お知らせ • Apr 30Eden Research plc Provides Revenue Guidance for the Fifteen Months Ending 31 March 2026Eden Research plc provided revenue guidance for the fifteen months ending 31 March 2026. For the period, revenue is expected to be c. £4.9 million.お知らせ • Jan 22Eden Research plc Provides Revenue Guidance for the Full Year of 2023Eden Research plc provided revenue guidance for the full year of 2023. For full year, revenue is expected to have increased by approximately 72% to £3.1 million, £0.3 million, or 11%, ahead of market expectations of £2.8 million(Fiscal Year 2022: £1.8 million).お知らせ • Jan 10Eden Research plc Provides Revenue Guidance for the Full Year of 2022Eden Research plc provided revenue guidance for the full year of 2022. For full year, revenue is expected to have increased by approximately 50% to £1.8 million, £0.1 million, or 6%, ahead of market expectations of £1.7 million (Fiscal Year 2021: £1.2 million).すべての更新を表示Recent updatesお知らせ • Apr 30Eden Research plc Provides Revenue Guidance for the Fifteen Months Ending 31 March 2026Eden Research plc provided revenue guidance for the fifteen months ending 31 March 2026. For the period, revenue is expected to be c. £4.9 million.お知らせ • Feb 06Eden Research plc has completed a Follow-on Equity Offering in the amount of £0.150419 million.Eden Research plc has completed a Follow-on Equity Offering in the amount of £0.150419 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 3,760,473 Price\Range: £0.04お知らせ • Feb 02+ 1 more updateEden Research plc has filed a Follow-on Equity Offering in the amount of £0.5 million.Eden Research plc has filed a Follow-on Equity Offering in the amount of £0.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 12,500,000 Price\Range: £0.04お知らせ • Jan 07Eden Research plc Announces Mevalone Label Extension in FranceEden Research plc announced that Mevalone has been granted approval by the French authorities for use on grapes to control downy and powdery mildew, subject to customary restrictions. France is one of the world's largest and most affected markets for grape downy mildew, and this is driving steady demand for conventional fungicides, biopesticides, and resistant varieties across its more- than 780,000 hectares of vines. While any estimate is subject to ever-evolving regulatory and commercial circumstances, the Company currently estimates that the potential peak revenue for this opportunity (with its current label extension conditions on the timing of applications) to be in the region of up to EUR8 million per annum. Given the timing of receipt of this label extension for two new diseases and the industry's schedule for marketing and stocking products for the growing season, the Company is not changing its market guidance at this stage but will monitor this as the season develops.お知らせ • Nov 22Eden Research plc Announces 3Logy Receives Approval by the Italian Authorities for Use on Several New CropesEden Research plc announced that 3LOGY (predominantly known as Mevalone®? outside of Italy) has been granted approval by the Italian authorities for use on numerous new crops in order to control Botrytis and a range of new diseases, including powdery mildew and Sclerotinia. The label for 3LOGY has been expanded over time from a specialised fungicide for grey mould (Botrytis cinerea) in grapes to a broad-spectrum fungicide for multiple horticultural crops following its first label extension in Italy in 2022. Now a leading biofungicide in the Italian market, 3LOGY has efficacy on crops that require the highest quality standards, including leafy vegetables, table grapes, and kiwis. The new crops approved for 3LOGY include legumes (such as peas, lentils, and chickpeas) as well as other crops such as avocado, carrot, radish, celery and asparagus. Together, the new label extensions grow the addressable market in Italy by more than twenty thousand hectares and provide 3LOGY with the opportunity to play a key role in the sustainable cultivation of these high-value crops. Beyond the enlarged addressable market in Italy, 3LOGY offers additional value for growers simply due to the extensive list of crops on which it can now be used. This versatility allows farmers to use it as a reference fungicide across cultivated open fields and in greenhouses for certain crops. This label extension reflects Eden's ongoing strategy to grow its core business through the addition of not only new products, but also through the expansion of regulatory authorisations for existing products that have substantial additional potential beyond simple territorial expansions. This label extension enhances Eden's competitive position within the fungicide segment. Sipcam Italia and 3LOGY are now considered top-of-mind products for Italian growers in a market with limited options. Although the potential sales gains are difficult to quantify.お知らせ • Nov 18Eden Research plc Announces Ecovelex 2025 Approval in ItalyEden Research plc announced that Ecovelextm 2025 has been granted temporary approval in Italy (in accordance with Reg. EU/1107/2009) for use as a bird repellent seed treatment on maize for the 2026 growing season. The temporary approval in Italy enables Eden to sell Ecovelex whilst await full EU-wide authorisation, which is expected in due course. Ecovelex represents a new entrant into the seed treatment market and is a replacement for conventional chemicals that are no longer approved in the EU and UK. It was developed to safely tackle crop destruction caused by birds - a major cause of losses in maize and other crops. Ecovelex works by emitting an unpleasant taste or odour that repels birds, leaving the seeds safely intact and the birds unaffected and free to find alternative food sources. The product, developed by Eden at its Oxfordshire facility, is based on Eden's plant-derived active ingredients, which the Company has registered in the EU, US, Mexico and elsewhere. Ecovelex has also been formulated using Eden's Sustaine®? plastic-free microencapsulation system. It is designed to support farmers as they strive to meet consumer and regulatory demands for more sustainable agriculture. In 2023, Eden submitted the regulatory dossier and application to Austria, which is acting as the interzonal rapporteur member state on behalf of the EU. Authorisation is expected in due course, with each EU member state then required to ratify the authorisation or request additional information before granting local authorisations.お知らせ • Sep 15Eden Research plc to Report First Half, 2025 Results on Sep 17, 2025Eden Research plc announced that they will report first half, 2025 results on Sep 17, 2025お知らせ • May 29Eden Research plc, Annual General Meeting, Jun 18, 2025Eden Research plc, Annual General Meeting, Jun 18, 2025. Location: one bartholomew close, ec1a 7bl, london United Kingdomお知らせ • Dec 20Eden Research plc Receives Regulatory Approval in Mexico for Novellus+ in MexicoEden Research plc announced that it has received regulatory approval in Mexico for Novellus®?+, a new, enhanced version of its fungicide, Mevalone O. The product's regulatory approval applies to its use against botrytis on a range of horticultural crops, comprising grapes, tomatoes, peppers, potatoes, strawberries, blueberries, raspberries, Gooseberries, eggplant, okra, as well as several other high value fruit and vegetables. Novellus+ will be exclusively distributed and sold by Sipcam Oxon's Mexican subsidiary, Advan Mexico SA de CV ("Advan"). This is also an exciting development as Novellus+ represents an evolution of Mevalone, allowing improved rates in the field, high levels of efficacy and a broader list of targets, all contributing to a larger addressable market in select territories. Registration efforts are also well underway in several additional countries, and the company look forward to providing further updates on the growth of Novellus+ within portfolio. The company believe that the sustainability and efficacy of Novellus+ will stand company product apart in a growing market, particularly as local regulations increasingly demand strict control of pesticide residues on fruit and vegetables in order to meet consumer expectations and international standards. This milestone further strengthens the product development pipeline in key markets where Sipcam Oxon operates through its affiliates. With its high-value crops and vegetables, primarily grown for export, Mexico offers significant market potential for botanical products like Novellus+. The successful development of Novellus+ highlights the fruitful collaboration between Eden and Sipcam, combining their expertise to create an enhanced formulation that delivers consistent efficacy and versatility.お知らせ • Dec 13Eden Research plc Announces That Its Fungicide, Mevalone Has Been Registered as an input for Organic Farming in GermanyEden Research plc announced that its fungicide, Mevalone, has been registered as an input for organic farming in Germany. The Input List for organic production in Germany is managed by the Research Institute of Organic Agriculture, FiBL, a European organisation with presence in several countries and with well-recognised and respected activities related to sustainability and organic farming. This inclusion has been granted by experts who evaluate farming inputs for their compliance with the requirements of organic production in Germany and multiple other countries. The news follows the approval of Mevalone in Germany, announced in August 2024. Eden's German commercial partner, Sumi Agro Deutschland, which has a strong focus on supporting organic farmers, has reinforced the importance of having this registration by FiBL Germany to better address the needs of organic growers in Germany. This policy exceeds the 25% of organic farmland in the EU as set in the EU Green Deal and means that significant action is required by the entire agriculture sector to reach this goal. Therefore, the registration of Mevalone as an input fororganic farming in Germany positions the product as a significant contributor to support German farmers to achieve their targets whilst also retaining productivity. With FiBL Germany's addition of Mevalone to the Organic Input list, Eden expects its fungicide to become an even more versatile product used by German organic growers to effectively control fungal diseases and to avoid production loss, whilst also remaining consistent with the requirements of organic agriculture.New Risk • Nov 01New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -UK£4.4m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£4.4m free cash flow). Earnings have declined by 31% per year over the past 5 years. Minor Risk Market cap is less than US$100m (€24.1m market cap, or US$26.2m).お知らせ • Oct 08Eden Research Delists from the OTCQB Exchange in the USEden Research plc announced that it has, as of October 8, 2024, delisted from the OTCQB exchange in the US. Following a review of its capital markets strategy, the Board of Eden has taken the decision to delist the Company from the US-based OTCQB exchange in light of the low trading activity of the Company's ordinary shares on that exchange. The delisting will have no impact on the Company's ordinary shares, which will continue to trade on AIM.Reported Earnings • Sep 26First half 2024 earnings released: UK£0.002 loss per share (vs UK£0.015 loss in 1H 2023)First half 2024 results: UK£0.002 loss per share (improved from UK£0.015 loss in 1H 2023). Revenue: UK£1.89m (up 65% from 1H 2023). Net loss: UK£916.1k (loss narrowed 84% from 1H 2023). Over the last 3 years on average, earnings per share has fallen by 19% per year and the company’s share price has also fallen by 19% per year.お知らせ • Sep 20Eden Research plc to Report First Half, 2024 Results on Sep 23, 2024Eden Research plc announced that they will report first half, 2024 results on Sep 23, 2024お知らせ • Sep 02Eden Research plc Announces Temporary Approval for Cedroz in GreeceEden Research plc announced that Cedroz has been granted, according to Reg. EU/1107/2009, a temporary approval in Greece for use on potatoes against wireworms for the 2024 growing season. Cedroz, whose distributor in Greece is Eastman Chemical; Eden's commercial partner in a number of countries, will now be permitted for use on potatoes against wireworms. Wireworms are the larvae of click beetles which cause damage to potatoes by forming a mass of holes and mini-tunnels on the vegetables. This pest is becoming increasingly problematic in many crops and regions, and farmers have very few options (most of them based on synthetic insecticides) to minimise its negative impact on the harvest. The Wireworm-infected area of potatoes grown in Greece alone is around 5,000 to 6,000 hectares, meaning that there is a sizeable, commercial opportunity for Cedroz beyond its consolidated uses as a post-planting nematicide in horticultural crops.お知らせ • Aug 15Eden Research plc Announces Executive ChangesEden Research plc announced the appointment of Ilshad Moulan as the Company's new Head of Regulatory Affairs. Ilshad will bring his experience in the agrochemical sector to lead Eden Research's regulatory strategy and execution, helping to ensure the successful global registration of its innovative crop protection solutions. Ilshad has strong expertise in regulatory affairs management having led teams and managed complex projects across the industry. With a BSc degree in Biochemistry and Cell Biology and an MSc degree in Crop Protection and Regulatory Science, his strong scientific background complements his regulatory expertise. At Dr. Knoell Consult Ltd, Ilshad led a team of nine, focusing on regulatory affairs. His career began at Agrauxine, where he played a key role in developing dossiers for biopesticide active ingredients and formulated plant protection products. Additionally, his previous roles at Evergreen Garden Care and Battelle involved supporting and managing regulatory submissions for conventional active ingredients and formulated products. Ilshad will be based at Eden Research's headquarters in Oxfordshire and will begin his new role immediately. He succeeds Dr. Mike Carroll who will retire at the end of a handover period. Mike has served as Eden's first-ever regulatory leader and played a key role in not only establishing Eden's in-house regulatory capabilities, but in successfully expanding the regulatory authorisations for Eden's existing and new products.お知らせ • Aug 13Eden Research plc Announces Biofungicide Regulatory Authorisation in GermanyEden Research plc announced that it has been granted regulatory authorisation for use of its biofungicide Mevalone in Germany. Mevalone is authorised for professional use on grapevines and apples to control Botrytis on grapes and for the prevention of storage diseases on apples. Renowned for its world-class white wines, Germany is the fourth largest wine-producing country in Europe. The nation is home to 13 designated wine regions accounting for a total area of 103,000 hectares. Germany is particularly famous for Riesling, a grape variety that produces some of the world's finest white wines and the most widely planted grape variety in Germany. In accordance with the EU's Green Deal and Farm to Fork Strategy, which aims to halve the use of pesticides by 2030 and increase consumer demand for organic produce, there has been a growing market drive to adopt more sustainable farming practices in the Central Europe region to reduce reliance on harmful conventional fungicides. With this latest approval, Eden Research alongside its commercial partner in the region, Sumi Agro Europe, will look to take a notable portion of Germany's biopesticide market share by providing local farmers with a sustainable alternative that performs in much the same way as conventional pesticides.お知らせ • Jul 17Eden Research plc Announces Appointment of Daniel Mulas García as Global Product and Marketing LeadEden Research plc announced the appointment of Daniel Mulas García as the Company's new Global Product and Marketing Leader with immediate effect. Daniel has extensive experience in sustainable crop protection, most recently working as Product Manager, Biostimulants and Biocontrol for Sipcam Iberia, an important commercial partner of Eden, for close to ten years. During his time with Sipcam, Daniel was responsible for the launch and management of many innovative crop protection and nutrition products, including playing a critical role in the success of Eden's Araw® biofungicide across the region. A key aspect of his role at Sipcam was to understand future trends in agriculture and regulation in order to address the needs of farmers by staying in close contact with key customers, influencers and policy makers to secure the full potential of the products within the portfolio. Daniel holds a Master's degree in Agronomical Engineering and a PhD in Agronomy from the Universidad de León. He will play a significant role as part of Eden's commercial team to help ensure that Eden's current and future products are well-aligned with the needs of farmers in an ever-changing regulatory and commercial environment. Daniel will also help the team to maximise revenue growth through the pursuit of ongoing expansions of the Company's product portfolio.お知らせ • Jun 24Eden Research plc Announces Biofungicide Label Extension in SpainEden Research plc announced that its flagship biofungicide has received authorisation for use in new crops and fungal pathogens in Spain. Mevalone®, marketed as Araw® in Spain by Sipcam Iberia (Sipcam), Eden's commercial partner in Spain, Portugal and several other countries, will now be permitted for use against powdery mildew on 22 new crops, botrytis cinerea on 20 new crops, rust disease on 8 new crops, and sclerotinia on 4 new crops. These new horticultural crops include a wide range of species such as avocados, kiwis, mangos, cherries, chickpeas, green beans, asparagus, leeks, and artichokes. Araw has been a well-established solution to prevent botrytis in grapes since it was launched in Spain in 2016. Following the first label expansion in 2021, Araw has become the reference biofungicide in a wide range of horticultural crops and berries, including blueberry, tomato, cucumber and lettuce. Araw helps growers to meet the highest quality standards and a large percentage of this produce is exported to other EU countries, as well as the UK and other premium markets. This has led to a significant increase in the commercialised volumes of Araw sold in Spain in recent years. This newly expanded label makes Araw one of the most versatile and reliable solutions to prevent fungal diseases in many crops under organic and conventional agriculture. Thanks to this new authorisation, obtained through Sipcam's local regulatory team, all relevant horticultural crops in Spain can now be protected with Araw representing an excellent opportunity in several crops of growing importance, such as avocado, mango, and almond, which has become the third largest tree crop in Spain after olives and grapes. Spain boasts the largest cultivated area of almond trees in the world and ranks third in terms of overall production. Eden anticipates that this growth of the addressable market for Araw will contribute to revenue in 2025 and beyond. Further details of this expansion will be provided in due course as commercialisation commences.お知らせ • Jun 13Eden Research plc Appoints Humair Tariq as New Global Commercial LeadEden Research plc announced the appointment of Humair Tariq as the Company's new Global Commercial Lead. Humair assumes his new role with immediate effect. Humair has considerable experience in the crop protection industry, most recently working for Syngenta as Portfolio Manager for biologicals, seed treatment and insect control. Prior to that, he held a series of global and regional positions with Syngenta in both Basel and Pakistan. Humair holds an MBA degree with a focus on marketing.Reported Earnings • Jun 07Full year 2023 earnings released: UK£0.015 loss per share (vs UK£0.006 loss in FY 2022)Full year 2023 results: UK£0.015 loss per share (further deteriorated from UK£0.006 loss in FY 2022). Revenue: UK£3.19m (up 75% from FY 2022). Net loss: UK£6.49m (loss widened 190% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has only fallen by 25% per year, which means it has not declined as severely as earnings.お知らせ • May 09+ 1 more updateEden Research plc to Report Fiscal Year 2023 Results on May 07, 2024Eden Research plc announced that they will report fiscal year 2023 results on May 07, 2024お知らせ • May 08Eden Research plc Announces Appointment of Derek Mcallan as Non-Executive Director and as Chairman of the Audit Committee Following the Company's 2024 AGMEden Research plc announced the appointment of Derek McAllan as a Non-Executive Director of the Company with immediate effect. Derek is currently a Partner of RSM UK, a leading provider of audit, tax and consulting services in the UK, where he is responsible for business development and client service across a portfolio of companies. Prior to his move to RSM UK in 2020, Derek acted as a Partner at KPMG for seventeen years during which he had a significant number of life science clients including some with which he worked from their inception to ultimate exit (including listings on NASDAQ and AIM, and also trade sales). Derek's portfolio of audit clients also included a number of AIM-listed companies. Derek will act as Chairman of the Audit Committee following the Company's 2024 Annual General Meeting (the "AGM"). The current Chairman of the Audit Committee, Robin Cridland, will remain a Non-Executive Director following the AGM to ensure an orderly handover to Derek.New Risk • May 07New major risk - Revenue and earnings growthEarnings have declined by 45% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 45% per year over the past 5 years. Minor Risks Currently unprofitable and not forecast to become profitable next year (UK£1.5m net loss next year). Share price has been volatile over the past 3 months (8.5% average weekly change). Shareholders have been diluted in the past year (40% increase in shares outstanding). Revenue is less than US$5m (UK£3.2m revenue, or US$4.0m). Market cap is less than US$100m (€25.6m market cap, or US$27.5m).Reported Earnings • May 07Full year 2023 earnings released: UK£0.015 loss per share (vs UK£0.006 loss in FY 2022)Full year 2023 results: UK£0.015 loss per share (further deteriorated from UK£0.006 loss in FY 2022). Revenue: UK£3.19m (up 75% from FY 2022). Net loss: UK£6.49m (loss widened 190% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 38% per year whereas the company’s share price has fallen by 33% per year.New Risk • Apr 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Currently unprofitable and not forecast to become profitable next year (UK£4.5m net loss next year). Share price has been volatile over the past 3 months (9.2% average weekly change). Shareholders have been diluted in the past year (40% increase in shares outstanding). Revenue is less than US$5m (UK£1.9m revenue, or US$2.4m). Market cap is less than US$100m (€30.0m market cap, or US$31.9m).Board Change • Feb 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 3 highly experienced directors. Independent Non-Executive Chairman Lykele van der Broek was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Jan 31Eden Research plc Announces Richard Horsman to Stepped Down as Non-Executive DirectorEden Research plc announced that Richard Horsman has stepped down as non-executive director with immediate effect.お知らせ • Jan 22Eden Research plc Provides Revenue Guidance for the Full Year of 2023Eden Research plc provided revenue guidance for the full year of 2023. For full year, revenue is expected to have increased by approximately 72% to £3.1 million, £0.3 million, or 11%, ahead of market expectations of £2.8 million(Fiscal Year 2022: £1.8 million).Reported Earnings • Oct 02First half 2023 earnings released: UK£0.015 loss per share (vs UK£0.003 loss in 1H 2022)First half 2023 results: UK£0.015 loss per share (further deteriorated from UK£0.003 loss in 1H 2022). Revenue: UK£1.14m (up 9.8% from 1H 2022). Net loss: UK£5.89m (loss widened 490% from 1H 2022).お知らせ • Sep 30Eden Research plc to Report First Half, 2023 Results on Sep 29, 2023Eden Research plc announced that they will report first half, 2023 results on Sep 29, 2023New Risk • Sep 19New major risk - Revenue and earnings growthEarnings have declined by 28% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£1.7m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 28% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (6.1% increase in shares outstanding). Revenue is less than US$5m (UK£1.8m revenue, or US$2.3m). Market cap is less than US$100m (€26.9m market cap, or US$28.8m).New Risk • Aug 04New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 6.1% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£1.7m free cash flow). Share price has been highly volatile over the past 3 months (23% average weekly change). Earnings have declined by 28% per year over the past 5 years. Minor Risks Currently unprofitable and not forecast to become profitable next year (UK£2.5m net loss next year). Shareholders have been diluted in the past year (6.1% increase in shares outstanding). Revenue is less than US$5m (UK£1.8m revenue, or US$2.3m). Market cap is less than US$100m (€30.4m market cap, or US$33.6m).お知らせ • Jul 04Eden Research plc Announces Regulatory Application for Authorised Use of Ecovelex™ in the United KingdomEden Research plc announced that it has applied for the authorisation of Ecovelex™ in its home country, the United Kingdom, following the recent application for authorisation in the European Union. Developed by Corteva Agriscience and Eden over the past three years, Ecovelex represents a new entrant into the seed treatment market and is intended to replace conventional chemicals banned in the EU and UK. It has been developed to tackle crop destruction caused by birds, a major cause of losses in maize and other crops. Ecovelex works by affecting the bird's olfactory system, creating an unpleasant taste or odour that repels the birds, leaving the seeds safely intact and the birds unaffected and free to find alternative food sources. The product is based on Eden's plant-derived chemistry and formulated using the Company's Sustaine® microencapsulation system, supporting farmers as they strive to meet consumer and regulator demands for more sustainable agriculture.お知らせ • Jun 09Eden Research plc, Annual General Meeting, Jun 29, 2023Eden Research plc, Annual General Meeting, Jun 29, 2023, at 10:00 Coordinated Universal Time. Location: 6-8 Tokenhouse Yard, EC2R 7AS London United Kingdom Agenda: To consider the annual report 2022; to confirm the appointment of PKF Littlejohn LLP as the Company's auditors to hold office until the conclusion of the next annual general meeting and to grant authority to the Directors to determine the auditors' remuneration; to elect as a Director, Richard Horsman, who, being eligible, is offering himself for election; to re-elect as a Director, Robin Cridland, who is voluntarily retiring and who, being eligible, is offering himself for re-election; and to discuss other matters.Reported Earnings • May 07Full year 2022 earnings released: UK£0.006 loss per share (vs UK£0.007 loss in FY 2021)Full year 2022 results: UK£0.006 loss per share (improved from UK£0.007 loss in FY 2021). Revenue: UK£1.83m (up 49% from FY 2021). Net loss: UK£2.24m (loss narrowed 20% from FY 2021).お知らせ • May 05Eden Research plc to Report Fiscal Year 2022 Results on May 05, 2023Eden Research plc announced that they will report fiscal year 2022 results on May 05, 2023お知らせ • Jan 31Eden Research plc Announces First Mevalone Authorisation for Domestic UseEden Research plc announced that its biofungicide, Mevalone, has received authorisation for home garden use in Italy for the control of a number of important plant pathogens affecting the home grower. The diseases include Botrytis cinerea and powdery mildew, destructive fungal pathogens affecting many plant species. Mevalone, which is marketed as 3LOGY in Italy, is already approved for agricultural use across a wide range of crops including: wine and table grapes, tomatoes, apple, pears, strawberries, cucumber, and many more. Approval for 3LOGY has now been granted for domestic use across a number of crops, allowing retailers to sell 3LOGY to gardeners in Italy for home applications. The use of 3LOGY affords farmers and home growers maximum flexibility in their plant and crop protection as it is free from residues and provides them the important benefit of avoiding higher-than-permitted pesticide residue levels as stipulated by the regulatory authorities. 3LOGY is distributed exclusively in Italy by Eden's distribution partner, Sipcam-Oxon (Sipcam). Based on natural active ingredients, 3LOGY is a useful tool in plant protection programmes and is aligned with the demanding requirements of integrated pest management programmes. Sipcam has extensive experience with 3LOGY and has also supported significant label extensions in Spain and Portugal. This approval will enable Sipcam to expand the market for 3LOGY into homes across Italy.お知らせ • Jan 10Eden Research plc Provides Revenue Guidance for the Full Year of 2022Eden Research plc provided revenue guidance for the full year of 2022. For full year, revenue is expected to have increased by approximately 50% to £1.8 million, £0.1 million, or 6%, ahead of market expectations of £1.7 million (Fiscal Year 2021: £1.2 million).Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Chairman Lykele van der Broek was the last independent director to join the board, commencing their role in 2017. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Oct 01First half 2022 earnings released: EPS: UK£0 (vs UK£0.004 loss in 1H 2021)First half 2022 results: EPS: UK£0. Revenue: UK£1.04m (up 32% from 1H 2021). Net loss: UK£997.6k (loss widened 26% from 1H 2021). Revenue is forecast to grow 44% p.a. on average during the next 2 years, compared to a 1.2% growth forecast for the Chemicals industry in Germany.お知らせ • Sep 27Eden Research plc Grants US EPA Regulatory ApprovalEden Research plc announced that it has received regulatory approval from the United States Environmental Protection Agency (EPA), for all five petitions submitted, covering the Company's three active ingredients (eugenol, geraniol and thymol) and two formulated products (Mevalone®and Cedroz™). The EPA approval of Eden's products and active ingredients will open significant revenue opportunities for Eden, with total market potential of approximately €94m for Mevalone and €189m for Cedroz. In addition, the Board expects that ultimately the registration of Eden's developmental insecticide will follow a shortened timeline as it is based upon the now-approved active ingredients. Eden will pursue registration of this new product in due course based upon the outcome of field trials. The total market potential for the insecticide is €237 million. The EPA authorisations are the result of over four years of effort by our experienced regulatory, development and commercial teams who worked tirelessly to ensure that Eden addressed the EPA's extensive and evolving list of strict requirements.お知らせ • Sep 02Eden Research plc Appoints Richard Horsman as Non-Executive Director, with effect from 1 September 2022Eden Research plc announced the appointment of Richard Horsman as Non-Executive Director, with effect from 1 September 2022. Richard brings over 25 years of AIM and Main Market experience to the team, having worked in both Executive and Non-Executive roles across a broad spectrum of businesses and industries. He has experience in delivering both organic and acquisition-based growth that will support Eden in delivering on its strategic objectives. Richard also has hands on agricultural experience, having owned and operated a commercial farm, and gaining a Diploma from Plumpton Agricultural College. Richard also holds non-executive roles at broadband, fixed line and mobile solutions business, Toople plc, and Gardien Group, a provider of software and services to the printed circuit board industry. Previous non-executive roles have included AIM-listed oil exploration and technology company Tomco plc, and specialty pharmaceutical business, Plethora Solutions plc.お知らせ • Jun 09Eden Research plc, Annual General Meeting, Jun 29, 2022Eden Research plc, Annual General Meeting, Jun 29, 2022, at 11:00 Coordinated Universal Time. Location: 10-11 Carlton House Terrace, St. James's London United KingdomReported Earnings • Jun 02Full year 2021 earnings released: UK£0.007 loss per share (vs UK£0.007 loss in FY 2020)Full year 2021 results: UK£0.007 loss per share (vs UK£0.007 loss in FY 2020). Revenue: UK£1.23m (down 10% from FY 2020). Net loss: UK£2.79m (loss widened 23% from FY 2020). Over the next year, revenue is forecast to grow 42%, compared to a 6.5% growth forecast for the industry in Germany.お知らせ • May 12Eden Research plc Announces Progress Towards EPA Approval and Further Authorisation in ItalyEden Research plc announced that it has passed a key milestone in the US for the approval of its products, Mevalone® and CedrozÔ. In addition, Eden's biofungicide, Mevalone®, has received authorisation for use on new crops in Italy for the control of the disease Botrytis cinerea, a destructive fungal pathogen affecting many plant species, as well as authorisation for use against additional fungal pathogens Powdery Mildew and Sclerotinia. The United States Environmental Protection Agency (EPA) has confirmed that it has granted Eden's plastic-free, microencapsulation technology, Sustaine®, an exemption from the requirement of a tolerance for residues in pesticide formulations in pre-harvest applications to crops. This is a key milestone with Eden now in the final stages of a process which should result in its three active ingredients (eugenol, geraniol and thymol) and two formulated products (Mevalone and Cedroz) receiving authorisation in the US in 2022. The addressable markets in the US, based on the products' current labels, are approximately €94m for Mevalone and €189m for Cedroz. With the demand for biopesticides such as these increasing significantly in the US due to rising regulatory restrictions for conventional chemicals, the tolerance exemption and subsequent approvals will present a significant opportunity for Eden. Mevalone is sold exclusively in Italy by Eden's commercial partner, Sipcam Oxon SpA ("Sipcam"), under the brand name "3logy®". Eden announces that it has been granted a label extension for 3logy in Italy, which authorises 3logy to be used against two new fungal pathogens and adds a number of new crop types to the label including berry fruits, tomato, watermelon, salad leaves, herbs, aubergines, cucumbers and peppers. Product applications are permitted close to the point of harvest, with most new uses having a pre-harvest interval of just one day. 3logy affords growers maximum flexibility in their crop protection programmes as it is free from residues and provides the important benefit of avoiding product rejections by wholesalers and food retailers which can result from higher-than-allowed pesticide residue levels. Sipcam has extensive experience with 3logy and has recently supported significant label extensions in Spain and Portugal as well as in Italy. This approval in Italy will enable Sipcam to expand the market for 3logy across thousands of hectares of new high value crops, such as strawberries where over 14,000 tonnes are exported from Italy alone on an annual basis.Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 1 highly experienced director. Independent Non-Executive Chairman Lykele van der Broek was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Oct 01First half 2021 earnings released: UK£0.004 loss per share (vs UK£0.004 loss in 1H 2020)The company reported a mediocre first half result with increased losses and weaker control over costs, although revenues improved. First half 2021 results: Revenue: UK£785.3k (up 31% from 1H 2020). Net loss: UK£1.58m (loss widened 54% from 1H 2020).お知らせ • Aug 27Eden Research plc Announces New Label Extension for Biofungicide in PortugalEden Research plc has received authorisation for use on new crops in Portugal (where it is marketed as Araw®) for the control of the disease Botrytis cinerea, a destructive fungal pathogen affecting many plant species. This latest label extension adds strawberries, raspberries, blueberries, cranberries, kiwi, aubergines and peppers to the label, with product applications being permitted close to the point of harvest. The use of Araw affords growers maximum flexibility in their crop protection programmes as it is free from residues and provides growers the important benefit of avoiding product rejections by wholesalers and food retailers that can result from higher-than-allowed pesticide residue levels.Reported Earnings • Jul 02Full year 2020 earnings released: UK£0.007 loss per share (vs UK£0.005 loss in FY 2019)The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: UK£1.37m (down 33% from FY 2019). Net loss: UK£2.27m (loss widened 98% from FY 2019).業績と収益の成長予測DB:9T7 - アナリストの将来予測と過去の財務データ ( )GBP Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/202810N/AN/AN/A13/31/20276-3-4013/31/20265-3-5-316/30/20254-2-20N/A3/31/20254-2-3-1N/A12/31/20244-2-4-1N/A9/30/20244-2-4-1N/A6/30/20244-2-4-2N/A3/31/20244-4-4-2N/A12/31/20233-6-3-2N/A9/30/20233-7-2-1N/A6/30/20232-7-10N/A3/31/20232-5-2-1N/A12/31/20222-2-2-1N/A9/30/20222-2-3-2N/A6/30/20221-2-4-2N/A3/31/20221-2-4-2N/A12/31/20211-3-3-2N/A9/30/20211-3-3-1N/A6/30/20212-3-30N/A3/31/20211-3-3-1N/A12/31/20201-2-3-1N/A9/30/20202-2-3-1N/A6/30/20202-2-2-1N/A3/31/20202-1-2-1N/A12/31/20192-1-2-1N/A9/30/20192-1-2-1N/A6/30/201930-1-1N/A3/31/201930N/A-1N/A12/31/201830N/A-1N/A9/30/20182-1N/A-1N/A6/30/20182-2N/A-1N/A3/31/20182-1N/A0N/A12/31/20172-1N/A0N/A9/30/20172-1N/A0N/A6/30/20171-1N/A0N/A3/31/20171-1N/A-1N/A12/31/20160-2N/A-1N/A9/30/20161-2N/A-1N/A6/30/20161-1N/A0N/A3/31/20161-1N/A0N/A12/31/20151-1N/A0N/A9/30/20151-2N/A0N/A6/30/20150-2N/A-1N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 9T7今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: 9T7今後 3 年間、利益が出ない状態が続くと予測されています。高成長収益: 9T7今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: 9T7の収益 ( 34.6% ) German市場 ( 6.5% ) よりも速いペースで成長すると予測されています。高い収益成長: 9T7の収益 ( 34.6% ) 20%よりも速いペースで成長すると予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 9T7の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YMaterials 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/07 08:50終値2026/05/07 00:00収益2025/06/30年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Eden Research plc 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。5 アナリスト機関Andrew Murray DarleyCavendishAdam McCarterCavendishChristopher DonnellanCavendish2 その他のアナリストを表示
お知らせ • Apr 30Eden Research plc Provides Revenue Guidance for the Fifteen Months Ending 31 March 2026Eden Research plc provided revenue guidance for the fifteen months ending 31 March 2026. For the period, revenue is expected to be c. £4.9 million.
お知らせ • Jan 22Eden Research plc Provides Revenue Guidance for the Full Year of 2023Eden Research plc provided revenue guidance for the full year of 2023. For full year, revenue is expected to have increased by approximately 72% to £3.1 million, £0.3 million, or 11%, ahead of market expectations of £2.8 million(Fiscal Year 2022: £1.8 million).
お知らせ • Jan 10Eden Research plc Provides Revenue Guidance for the Full Year of 2022Eden Research plc provided revenue guidance for the full year of 2022. For full year, revenue is expected to have increased by approximately 50% to £1.8 million, £0.1 million, or 6%, ahead of market expectations of £1.7 million (Fiscal Year 2021: £1.2 million).
お知らせ • Apr 30Eden Research plc Provides Revenue Guidance for the Fifteen Months Ending 31 March 2026Eden Research plc provided revenue guidance for the fifteen months ending 31 March 2026. For the period, revenue is expected to be c. £4.9 million.
お知らせ • Feb 06Eden Research plc has completed a Follow-on Equity Offering in the amount of £0.150419 million.Eden Research plc has completed a Follow-on Equity Offering in the amount of £0.150419 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 3,760,473 Price\Range: £0.04
お知らせ • Feb 02+ 1 more updateEden Research plc has filed a Follow-on Equity Offering in the amount of £0.5 million.Eden Research plc has filed a Follow-on Equity Offering in the amount of £0.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 12,500,000 Price\Range: £0.04
お知らせ • Jan 07Eden Research plc Announces Mevalone Label Extension in FranceEden Research plc announced that Mevalone has been granted approval by the French authorities for use on grapes to control downy and powdery mildew, subject to customary restrictions. France is one of the world's largest and most affected markets for grape downy mildew, and this is driving steady demand for conventional fungicides, biopesticides, and resistant varieties across its more- than 780,000 hectares of vines. While any estimate is subject to ever-evolving regulatory and commercial circumstances, the Company currently estimates that the potential peak revenue for this opportunity (with its current label extension conditions on the timing of applications) to be in the region of up to EUR8 million per annum. Given the timing of receipt of this label extension for two new diseases and the industry's schedule for marketing and stocking products for the growing season, the Company is not changing its market guidance at this stage but will monitor this as the season develops.
お知らせ • Nov 22Eden Research plc Announces 3Logy Receives Approval by the Italian Authorities for Use on Several New CropesEden Research plc announced that 3LOGY (predominantly known as Mevalone®? outside of Italy) has been granted approval by the Italian authorities for use on numerous new crops in order to control Botrytis and a range of new diseases, including powdery mildew and Sclerotinia. The label for 3LOGY has been expanded over time from a specialised fungicide for grey mould (Botrytis cinerea) in grapes to a broad-spectrum fungicide for multiple horticultural crops following its first label extension in Italy in 2022. Now a leading biofungicide in the Italian market, 3LOGY has efficacy on crops that require the highest quality standards, including leafy vegetables, table grapes, and kiwis. The new crops approved for 3LOGY include legumes (such as peas, lentils, and chickpeas) as well as other crops such as avocado, carrot, radish, celery and asparagus. Together, the new label extensions grow the addressable market in Italy by more than twenty thousand hectares and provide 3LOGY with the opportunity to play a key role in the sustainable cultivation of these high-value crops. Beyond the enlarged addressable market in Italy, 3LOGY offers additional value for growers simply due to the extensive list of crops on which it can now be used. This versatility allows farmers to use it as a reference fungicide across cultivated open fields and in greenhouses for certain crops. This label extension reflects Eden's ongoing strategy to grow its core business through the addition of not only new products, but also through the expansion of regulatory authorisations for existing products that have substantial additional potential beyond simple territorial expansions. This label extension enhances Eden's competitive position within the fungicide segment. Sipcam Italia and 3LOGY are now considered top-of-mind products for Italian growers in a market with limited options. Although the potential sales gains are difficult to quantify.
お知らせ • Nov 18Eden Research plc Announces Ecovelex 2025 Approval in ItalyEden Research plc announced that Ecovelextm 2025 has been granted temporary approval in Italy (in accordance with Reg. EU/1107/2009) for use as a bird repellent seed treatment on maize for the 2026 growing season. The temporary approval in Italy enables Eden to sell Ecovelex whilst await full EU-wide authorisation, which is expected in due course. Ecovelex represents a new entrant into the seed treatment market and is a replacement for conventional chemicals that are no longer approved in the EU and UK. It was developed to safely tackle crop destruction caused by birds - a major cause of losses in maize and other crops. Ecovelex works by emitting an unpleasant taste or odour that repels birds, leaving the seeds safely intact and the birds unaffected and free to find alternative food sources. The product, developed by Eden at its Oxfordshire facility, is based on Eden's plant-derived active ingredients, which the Company has registered in the EU, US, Mexico and elsewhere. Ecovelex has also been formulated using Eden's Sustaine®? plastic-free microencapsulation system. It is designed to support farmers as they strive to meet consumer and regulatory demands for more sustainable agriculture. In 2023, Eden submitted the regulatory dossier and application to Austria, which is acting as the interzonal rapporteur member state on behalf of the EU. Authorisation is expected in due course, with each EU member state then required to ratify the authorisation or request additional information before granting local authorisations.
お知らせ • Sep 15Eden Research plc to Report First Half, 2025 Results on Sep 17, 2025Eden Research plc announced that they will report first half, 2025 results on Sep 17, 2025
お知らせ • May 29Eden Research plc, Annual General Meeting, Jun 18, 2025Eden Research plc, Annual General Meeting, Jun 18, 2025. Location: one bartholomew close, ec1a 7bl, london United Kingdom
お知らせ • Dec 20Eden Research plc Receives Regulatory Approval in Mexico for Novellus+ in MexicoEden Research plc announced that it has received regulatory approval in Mexico for Novellus®?+, a new, enhanced version of its fungicide, Mevalone O. The product's regulatory approval applies to its use against botrytis on a range of horticultural crops, comprising grapes, tomatoes, peppers, potatoes, strawberries, blueberries, raspberries, Gooseberries, eggplant, okra, as well as several other high value fruit and vegetables. Novellus+ will be exclusively distributed and sold by Sipcam Oxon's Mexican subsidiary, Advan Mexico SA de CV ("Advan"). This is also an exciting development as Novellus+ represents an evolution of Mevalone, allowing improved rates in the field, high levels of efficacy and a broader list of targets, all contributing to a larger addressable market in select territories. Registration efforts are also well underway in several additional countries, and the company look forward to providing further updates on the growth of Novellus+ within portfolio. The company believe that the sustainability and efficacy of Novellus+ will stand company product apart in a growing market, particularly as local regulations increasingly demand strict control of pesticide residues on fruit and vegetables in order to meet consumer expectations and international standards. This milestone further strengthens the product development pipeline in key markets where Sipcam Oxon operates through its affiliates. With its high-value crops and vegetables, primarily grown for export, Mexico offers significant market potential for botanical products like Novellus+. The successful development of Novellus+ highlights the fruitful collaboration between Eden and Sipcam, combining their expertise to create an enhanced formulation that delivers consistent efficacy and versatility.
お知らせ • Dec 13Eden Research plc Announces That Its Fungicide, Mevalone Has Been Registered as an input for Organic Farming in GermanyEden Research plc announced that its fungicide, Mevalone, has been registered as an input for organic farming in Germany. The Input List for organic production in Germany is managed by the Research Institute of Organic Agriculture, FiBL, a European organisation with presence in several countries and with well-recognised and respected activities related to sustainability and organic farming. This inclusion has been granted by experts who evaluate farming inputs for their compliance with the requirements of organic production in Germany and multiple other countries. The news follows the approval of Mevalone in Germany, announced in August 2024. Eden's German commercial partner, Sumi Agro Deutschland, which has a strong focus on supporting organic farmers, has reinforced the importance of having this registration by FiBL Germany to better address the needs of organic growers in Germany. This policy exceeds the 25% of organic farmland in the EU as set in the EU Green Deal and means that significant action is required by the entire agriculture sector to reach this goal. Therefore, the registration of Mevalone as an input fororganic farming in Germany positions the product as a significant contributor to support German farmers to achieve their targets whilst also retaining productivity. With FiBL Germany's addition of Mevalone to the Organic Input list, Eden expects its fungicide to become an even more versatile product used by German organic growers to effectively control fungal diseases and to avoid production loss, whilst also remaining consistent with the requirements of organic agriculture.
New Risk • Nov 01New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -UK£4.4m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£4.4m free cash flow). Earnings have declined by 31% per year over the past 5 years. Minor Risk Market cap is less than US$100m (€24.1m market cap, or US$26.2m).
お知らせ • Oct 08Eden Research Delists from the OTCQB Exchange in the USEden Research plc announced that it has, as of October 8, 2024, delisted from the OTCQB exchange in the US. Following a review of its capital markets strategy, the Board of Eden has taken the decision to delist the Company from the US-based OTCQB exchange in light of the low trading activity of the Company's ordinary shares on that exchange. The delisting will have no impact on the Company's ordinary shares, which will continue to trade on AIM.
Reported Earnings • Sep 26First half 2024 earnings released: UK£0.002 loss per share (vs UK£0.015 loss in 1H 2023)First half 2024 results: UK£0.002 loss per share (improved from UK£0.015 loss in 1H 2023). Revenue: UK£1.89m (up 65% from 1H 2023). Net loss: UK£916.1k (loss narrowed 84% from 1H 2023). Over the last 3 years on average, earnings per share has fallen by 19% per year and the company’s share price has also fallen by 19% per year.
お知らせ • Sep 20Eden Research plc to Report First Half, 2024 Results on Sep 23, 2024Eden Research plc announced that they will report first half, 2024 results on Sep 23, 2024
お知らせ • Sep 02Eden Research plc Announces Temporary Approval for Cedroz in GreeceEden Research plc announced that Cedroz has been granted, according to Reg. EU/1107/2009, a temporary approval in Greece for use on potatoes against wireworms for the 2024 growing season. Cedroz, whose distributor in Greece is Eastman Chemical; Eden's commercial partner in a number of countries, will now be permitted for use on potatoes against wireworms. Wireworms are the larvae of click beetles which cause damage to potatoes by forming a mass of holes and mini-tunnels on the vegetables. This pest is becoming increasingly problematic in many crops and regions, and farmers have very few options (most of them based on synthetic insecticides) to minimise its negative impact on the harvest. The Wireworm-infected area of potatoes grown in Greece alone is around 5,000 to 6,000 hectares, meaning that there is a sizeable, commercial opportunity for Cedroz beyond its consolidated uses as a post-planting nematicide in horticultural crops.
お知らせ • Aug 15Eden Research plc Announces Executive ChangesEden Research plc announced the appointment of Ilshad Moulan as the Company's new Head of Regulatory Affairs. Ilshad will bring his experience in the agrochemical sector to lead Eden Research's regulatory strategy and execution, helping to ensure the successful global registration of its innovative crop protection solutions. Ilshad has strong expertise in regulatory affairs management having led teams and managed complex projects across the industry. With a BSc degree in Biochemistry and Cell Biology and an MSc degree in Crop Protection and Regulatory Science, his strong scientific background complements his regulatory expertise. At Dr. Knoell Consult Ltd, Ilshad led a team of nine, focusing on regulatory affairs. His career began at Agrauxine, where he played a key role in developing dossiers for biopesticide active ingredients and formulated plant protection products. Additionally, his previous roles at Evergreen Garden Care and Battelle involved supporting and managing regulatory submissions for conventional active ingredients and formulated products. Ilshad will be based at Eden Research's headquarters in Oxfordshire and will begin his new role immediately. He succeeds Dr. Mike Carroll who will retire at the end of a handover period. Mike has served as Eden's first-ever regulatory leader and played a key role in not only establishing Eden's in-house regulatory capabilities, but in successfully expanding the regulatory authorisations for Eden's existing and new products.
お知らせ • Aug 13Eden Research plc Announces Biofungicide Regulatory Authorisation in GermanyEden Research plc announced that it has been granted regulatory authorisation for use of its biofungicide Mevalone in Germany. Mevalone is authorised for professional use on grapevines and apples to control Botrytis on grapes and for the prevention of storage diseases on apples. Renowned for its world-class white wines, Germany is the fourth largest wine-producing country in Europe. The nation is home to 13 designated wine regions accounting for a total area of 103,000 hectares. Germany is particularly famous for Riesling, a grape variety that produces some of the world's finest white wines and the most widely planted grape variety in Germany. In accordance with the EU's Green Deal and Farm to Fork Strategy, which aims to halve the use of pesticides by 2030 and increase consumer demand for organic produce, there has been a growing market drive to adopt more sustainable farming practices in the Central Europe region to reduce reliance on harmful conventional fungicides. With this latest approval, Eden Research alongside its commercial partner in the region, Sumi Agro Europe, will look to take a notable portion of Germany's biopesticide market share by providing local farmers with a sustainable alternative that performs in much the same way as conventional pesticides.
お知らせ • Jul 17Eden Research plc Announces Appointment of Daniel Mulas García as Global Product and Marketing LeadEden Research plc announced the appointment of Daniel Mulas García as the Company's new Global Product and Marketing Leader with immediate effect. Daniel has extensive experience in sustainable crop protection, most recently working as Product Manager, Biostimulants and Biocontrol for Sipcam Iberia, an important commercial partner of Eden, for close to ten years. During his time with Sipcam, Daniel was responsible for the launch and management of many innovative crop protection and nutrition products, including playing a critical role in the success of Eden's Araw® biofungicide across the region. A key aspect of his role at Sipcam was to understand future trends in agriculture and regulation in order to address the needs of farmers by staying in close contact with key customers, influencers and policy makers to secure the full potential of the products within the portfolio. Daniel holds a Master's degree in Agronomical Engineering and a PhD in Agronomy from the Universidad de León. He will play a significant role as part of Eden's commercial team to help ensure that Eden's current and future products are well-aligned with the needs of farmers in an ever-changing regulatory and commercial environment. Daniel will also help the team to maximise revenue growth through the pursuit of ongoing expansions of the Company's product portfolio.
お知らせ • Jun 24Eden Research plc Announces Biofungicide Label Extension in SpainEden Research plc announced that its flagship biofungicide has received authorisation for use in new crops and fungal pathogens in Spain. Mevalone®, marketed as Araw® in Spain by Sipcam Iberia (Sipcam), Eden's commercial partner in Spain, Portugal and several other countries, will now be permitted for use against powdery mildew on 22 new crops, botrytis cinerea on 20 new crops, rust disease on 8 new crops, and sclerotinia on 4 new crops. These new horticultural crops include a wide range of species such as avocados, kiwis, mangos, cherries, chickpeas, green beans, asparagus, leeks, and artichokes. Araw has been a well-established solution to prevent botrytis in grapes since it was launched in Spain in 2016. Following the first label expansion in 2021, Araw has become the reference biofungicide in a wide range of horticultural crops and berries, including blueberry, tomato, cucumber and lettuce. Araw helps growers to meet the highest quality standards and a large percentage of this produce is exported to other EU countries, as well as the UK and other premium markets. This has led to a significant increase in the commercialised volumes of Araw sold in Spain in recent years. This newly expanded label makes Araw one of the most versatile and reliable solutions to prevent fungal diseases in many crops under organic and conventional agriculture. Thanks to this new authorisation, obtained through Sipcam's local regulatory team, all relevant horticultural crops in Spain can now be protected with Araw representing an excellent opportunity in several crops of growing importance, such as avocado, mango, and almond, which has become the third largest tree crop in Spain after olives and grapes. Spain boasts the largest cultivated area of almond trees in the world and ranks third in terms of overall production. Eden anticipates that this growth of the addressable market for Araw will contribute to revenue in 2025 and beyond. Further details of this expansion will be provided in due course as commercialisation commences.
お知らせ • Jun 13Eden Research plc Appoints Humair Tariq as New Global Commercial LeadEden Research plc announced the appointment of Humair Tariq as the Company's new Global Commercial Lead. Humair assumes his new role with immediate effect. Humair has considerable experience in the crop protection industry, most recently working for Syngenta as Portfolio Manager for biologicals, seed treatment and insect control. Prior to that, he held a series of global and regional positions with Syngenta in both Basel and Pakistan. Humair holds an MBA degree with a focus on marketing.
Reported Earnings • Jun 07Full year 2023 earnings released: UK£0.015 loss per share (vs UK£0.006 loss in FY 2022)Full year 2023 results: UK£0.015 loss per share (further deteriorated from UK£0.006 loss in FY 2022). Revenue: UK£3.19m (up 75% from FY 2022). Net loss: UK£6.49m (loss widened 190% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has only fallen by 25% per year, which means it has not declined as severely as earnings.
お知らせ • May 09+ 1 more updateEden Research plc to Report Fiscal Year 2023 Results on May 07, 2024Eden Research plc announced that they will report fiscal year 2023 results on May 07, 2024
お知らせ • May 08Eden Research plc Announces Appointment of Derek Mcallan as Non-Executive Director and as Chairman of the Audit Committee Following the Company's 2024 AGMEden Research plc announced the appointment of Derek McAllan as a Non-Executive Director of the Company with immediate effect. Derek is currently a Partner of RSM UK, a leading provider of audit, tax and consulting services in the UK, where he is responsible for business development and client service across a portfolio of companies. Prior to his move to RSM UK in 2020, Derek acted as a Partner at KPMG for seventeen years during which he had a significant number of life science clients including some with which he worked from their inception to ultimate exit (including listings on NASDAQ and AIM, and also trade sales). Derek's portfolio of audit clients also included a number of AIM-listed companies. Derek will act as Chairman of the Audit Committee following the Company's 2024 Annual General Meeting (the "AGM"). The current Chairman of the Audit Committee, Robin Cridland, will remain a Non-Executive Director following the AGM to ensure an orderly handover to Derek.
New Risk • May 07New major risk - Revenue and earnings growthEarnings have declined by 45% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 45% per year over the past 5 years. Minor Risks Currently unprofitable and not forecast to become profitable next year (UK£1.5m net loss next year). Share price has been volatile over the past 3 months (8.5% average weekly change). Shareholders have been diluted in the past year (40% increase in shares outstanding). Revenue is less than US$5m (UK£3.2m revenue, or US$4.0m). Market cap is less than US$100m (€25.6m market cap, or US$27.5m).
Reported Earnings • May 07Full year 2023 earnings released: UK£0.015 loss per share (vs UK£0.006 loss in FY 2022)Full year 2023 results: UK£0.015 loss per share (further deteriorated from UK£0.006 loss in FY 2022). Revenue: UK£3.19m (up 75% from FY 2022). Net loss: UK£6.49m (loss widened 190% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 38% per year whereas the company’s share price has fallen by 33% per year.
New Risk • Apr 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Currently unprofitable and not forecast to become profitable next year (UK£4.5m net loss next year). Share price has been volatile over the past 3 months (9.2% average weekly change). Shareholders have been diluted in the past year (40% increase in shares outstanding). Revenue is less than US$5m (UK£1.9m revenue, or US$2.4m). Market cap is less than US$100m (€30.0m market cap, or US$31.9m).
Board Change • Feb 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 3 highly experienced directors. Independent Non-Executive Chairman Lykele van der Broek was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Jan 31Eden Research plc Announces Richard Horsman to Stepped Down as Non-Executive DirectorEden Research plc announced that Richard Horsman has stepped down as non-executive director with immediate effect.
お知らせ • Jan 22Eden Research plc Provides Revenue Guidance for the Full Year of 2023Eden Research plc provided revenue guidance for the full year of 2023. For full year, revenue is expected to have increased by approximately 72% to £3.1 million, £0.3 million, or 11%, ahead of market expectations of £2.8 million(Fiscal Year 2022: £1.8 million).
Reported Earnings • Oct 02First half 2023 earnings released: UK£0.015 loss per share (vs UK£0.003 loss in 1H 2022)First half 2023 results: UK£0.015 loss per share (further deteriorated from UK£0.003 loss in 1H 2022). Revenue: UK£1.14m (up 9.8% from 1H 2022). Net loss: UK£5.89m (loss widened 490% from 1H 2022).
お知らせ • Sep 30Eden Research plc to Report First Half, 2023 Results on Sep 29, 2023Eden Research plc announced that they will report first half, 2023 results on Sep 29, 2023
New Risk • Sep 19New major risk - Revenue and earnings growthEarnings have declined by 28% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£1.7m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 28% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (6.1% increase in shares outstanding). Revenue is less than US$5m (UK£1.8m revenue, or US$2.3m). Market cap is less than US$100m (€26.9m market cap, or US$28.8m).
New Risk • Aug 04New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 6.1% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£1.7m free cash flow). Share price has been highly volatile over the past 3 months (23% average weekly change). Earnings have declined by 28% per year over the past 5 years. Minor Risks Currently unprofitable and not forecast to become profitable next year (UK£2.5m net loss next year). Shareholders have been diluted in the past year (6.1% increase in shares outstanding). Revenue is less than US$5m (UK£1.8m revenue, or US$2.3m). Market cap is less than US$100m (€30.4m market cap, or US$33.6m).
お知らせ • Jul 04Eden Research plc Announces Regulatory Application for Authorised Use of Ecovelex™ in the United KingdomEden Research plc announced that it has applied for the authorisation of Ecovelex™ in its home country, the United Kingdom, following the recent application for authorisation in the European Union. Developed by Corteva Agriscience and Eden over the past three years, Ecovelex represents a new entrant into the seed treatment market and is intended to replace conventional chemicals banned in the EU and UK. It has been developed to tackle crop destruction caused by birds, a major cause of losses in maize and other crops. Ecovelex works by affecting the bird's olfactory system, creating an unpleasant taste or odour that repels the birds, leaving the seeds safely intact and the birds unaffected and free to find alternative food sources. The product is based on Eden's plant-derived chemistry and formulated using the Company's Sustaine® microencapsulation system, supporting farmers as they strive to meet consumer and regulator demands for more sustainable agriculture.
お知らせ • Jun 09Eden Research plc, Annual General Meeting, Jun 29, 2023Eden Research plc, Annual General Meeting, Jun 29, 2023, at 10:00 Coordinated Universal Time. Location: 6-8 Tokenhouse Yard, EC2R 7AS London United Kingdom Agenda: To consider the annual report 2022; to confirm the appointment of PKF Littlejohn LLP as the Company's auditors to hold office until the conclusion of the next annual general meeting and to grant authority to the Directors to determine the auditors' remuneration; to elect as a Director, Richard Horsman, who, being eligible, is offering himself for election; to re-elect as a Director, Robin Cridland, who is voluntarily retiring and who, being eligible, is offering himself for re-election; and to discuss other matters.
Reported Earnings • May 07Full year 2022 earnings released: UK£0.006 loss per share (vs UK£0.007 loss in FY 2021)Full year 2022 results: UK£0.006 loss per share (improved from UK£0.007 loss in FY 2021). Revenue: UK£1.83m (up 49% from FY 2021). Net loss: UK£2.24m (loss narrowed 20% from FY 2021).
お知らせ • May 05Eden Research plc to Report Fiscal Year 2022 Results on May 05, 2023Eden Research plc announced that they will report fiscal year 2022 results on May 05, 2023
お知らせ • Jan 31Eden Research plc Announces First Mevalone Authorisation for Domestic UseEden Research plc announced that its biofungicide, Mevalone, has received authorisation for home garden use in Italy for the control of a number of important plant pathogens affecting the home grower. The diseases include Botrytis cinerea and powdery mildew, destructive fungal pathogens affecting many plant species. Mevalone, which is marketed as 3LOGY in Italy, is already approved for agricultural use across a wide range of crops including: wine and table grapes, tomatoes, apple, pears, strawberries, cucumber, and many more. Approval for 3LOGY has now been granted for domestic use across a number of crops, allowing retailers to sell 3LOGY to gardeners in Italy for home applications. The use of 3LOGY affords farmers and home growers maximum flexibility in their plant and crop protection as it is free from residues and provides them the important benefit of avoiding higher-than-permitted pesticide residue levels as stipulated by the regulatory authorities. 3LOGY is distributed exclusively in Italy by Eden's distribution partner, Sipcam-Oxon (Sipcam). Based on natural active ingredients, 3LOGY is a useful tool in plant protection programmes and is aligned with the demanding requirements of integrated pest management programmes. Sipcam has extensive experience with 3LOGY and has also supported significant label extensions in Spain and Portugal. This approval will enable Sipcam to expand the market for 3LOGY into homes across Italy.
お知らせ • Jan 10Eden Research plc Provides Revenue Guidance for the Full Year of 2022Eden Research plc provided revenue guidance for the full year of 2022. For full year, revenue is expected to have increased by approximately 50% to £1.8 million, £0.1 million, or 6%, ahead of market expectations of £1.7 million (Fiscal Year 2021: £1.2 million).
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Chairman Lykele van der Broek was the last independent director to join the board, commencing their role in 2017. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Oct 01First half 2022 earnings released: EPS: UK£0 (vs UK£0.004 loss in 1H 2021)First half 2022 results: EPS: UK£0. Revenue: UK£1.04m (up 32% from 1H 2021). Net loss: UK£997.6k (loss widened 26% from 1H 2021). Revenue is forecast to grow 44% p.a. on average during the next 2 years, compared to a 1.2% growth forecast for the Chemicals industry in Germany.
お知らせ • Sep 27Eden Research plc Grants US EPA Regulatory ApprovalEden Research plc announced that it has received regulatory approval from the United States Environmental Protection Agency (EPA), for all five petitions submitted, covering the Company's three active ingredients (eugenol, geraniol and thymol) and two formulated products (Mevalone®and Cedroz™). The EPA approval of Eden's products and active ingredients will open significant revenue opportunities for Eden, with total market potential of approximately €94m for Mevalone and €189m for Cedroz. In addition, the Board expects that ultimately the registration of Eden's developmental insecticide will follow a shortened timeline as it is based upon the now-approved active ingredients. Eden will pursue registration of this new product in due course based upon the outcome of field trials. The total market potential for the insecticide is €237 million. The EPA authorisations are the result of over four years of effort by our experienced regulatory, development and commercial teams who worked tirelessly to ensure that Eden addressed the EPA's extensive and evolving list of strict requirements.
お知らせ • Sep 02Eden Research plc Appoints Richard Horsman as Non-Executive Director, with effect from 1 September 2022Eden Research plc announced the appointment of Richard Horsman as Non-Executive Director, with effect from 1 September 2022. Richard brings over 25 years of AIM and Main Market experience to the team, having worked in both Executive and Non-Executive roles across a broad spectrum of businesses and industries. He has experience in delivering both organic and acquisition-based growth that will support Eden in delivering on its strategic objectives. Richard also has hands on agricultural experience, having owned and operated a commercial farm, and gaining a Diploma from Plumpton Agricultural College. Richard also holds non-executive roles at broadband, fixed line and mobile solutions business, Toople plc, and Gardien Group, a provider of software and services to the printed circuit board industry. Previous non-executive roles have included AIM-listed oil exploration and technology company Tomco plc, and specialty pharmaceutical business, Plethora Solutions plc.
お知らせ • Jun 09Eden Research plc, Annual General Meeting, Jun 29, 2022Eden Research plc, Annual General Meeting, Jun 29, 2022, at 11:00 Coordinated Universal Time. Location: 10-11 Carlton House Terrace, St. James's London United Kingdom
Reported Earnings • Jun 02Full year 2021 earnings released: UK£0.007 loss per share (vs UK£0.007 loss in FY 2020)Full year 2021 results: UK£0.007 loss per share (vs UK£0.007 loss in FY 2020). Revenue: UK£1.23m (down 10% from FY 2020). Net loss: UK£2.79m (loss widened 23% from FY 2020). Over the next year, revenue is forecast to grow 42%, compared to a 6.5% growth forecast for the industry in Germany.
お知らせ • May 12Eden Research plc Announces Progress Towards EPA Approval and Further Authorisation in ItalyEden Research plc announced that it has passed a key milestone in the US for the approval of its products, Mevalone® and CedrozÔ. In addition, Eden's biofungicide, Mevalone®, has received authorisation for use on new crops in Italy for the control of the disease Botrytis cinerea, a destructive fungal pathogen affecting many plant species, as well as authorisation for use against additional fungal pathogens Powdery Mildew and Sclerotinia. The United States Environmental Protection Agency (EPA) has confirmed that it has granted Eden's plastic-free, microencapsulation technology, Sustaine®, an exemption from the requirement of a tolerance for residues in pesticide formulations in pre-harvest applications to crops. This is a key milestone with Eden now in the final stages of a process which should result in its three active ingredients (eugenol, geraniol and thymol) and two formulated products (Mevalone and Cedroz) receiving authorisation in the US in 2022. The addressable markets in the US, based on the products' current labels, are approximately €94m for Mevalone and €189m for Cedroz. With the demand for biopesticides such as these increasing significantly in the US due to rising regulatory restrictions for conventional chemicals, the tolerance exemption and subsequent approvals will present a significant opportunity for Eden. Mevalone is sold exclusively in Italy by Eden's commercial partner, Sipcam Oxon SpA ("Sipcam"), under the brand name "3logy®". Eden announces that it has been granted a label extension for 3logy in Italy, which authorises 3logy to be used against two new fungal pathogens and adds a number of new crop types to the label including berry fruits, tomato, watermelon, salad leaves, herbs, aubergines, cucumbers and peppers. Product applications are permitted close to the point of harvest, with most new uses having a pre-harvest interval of just one day. 3logy affords growers maximum flexibility in their crop protection programmes as it is free from residues and provides the important benefit of avoiding product rejections by wholesalers and food retailers which can result from higher-than-allowed pesticide residue levels. Sipcam has extensive experience with 3logy and has recently supported significant label extensions in Spain and Portugal as well as in Italy. This approval in Italy will enable Sipcam to expand the market for 3logy across thousands of hectares of new high value crops, such as strawberries where over 14,000 tonnes are exported from Italy alone on an annual basis.
Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 1 highly experienced director. Independent Non-Executive Chairman Lykele van der Broek was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Oct 01First half 2021 earnings released: UK£0.004 loss per share (vs UK£0.004 loss in 1H 2020)The company reported a mediocre first half result with increased losses and weaker control over costs, although revenues improved. First half 2021 results: Revenue: UK£785.3k (up 31% from 1H 2020). Net loss: UK£1.58m (loss widened 54% from 1H 2020).
お知らせ • Aug 27Eden Research plc Announces New Label Extension for Biofungicide in PortugalEden Research plc has received authorisation for use on new crops in Portugal (where it is marketed as Araw®) for the control of the disease Botrytis cinerea, a destructive fungal pathogen affecting many plant species. This latest label extension adds strawberries, raspberries, blueberries, cranberries, kiwi, aubergines and peppers to the label, with product applications being permitted close to the point of harvest. The use of Araw affords growers maximum flexibility in their crop protection programmes as it is free from residues and provides growers the important benefit of avoiding product rejections by wholesalers and food retailers that can result from higher-than-allowed pesticide residue levels.
Reported Earnings • Jul 02Full year 2020 earnings released: UK£0.007 loss per share (vs UK£0.005 loss in FY 2019)The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: UK£1.37m (down 33% from FY 2019). Net loss: UK£2.27m (loss widened 98% from FY 2019).